Last 12 months
Inside the activity.
2 purchase rows · 116 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 15 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 29 |
| Feb 2026 | 0 | 7 |
| Mar 2026 | 0 | 31 |
| Apr 2026 | 0 | 9 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 11 |
| Jul 2026 | 2 | 6 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2026 Filed Mar 5, 2026 23:14 UTC |
LOSCALZO JOSEPHDirector
|
Exercise / conversionCommon Stock | 200 | $38.06 | $7,612.00 |
DisclosureSEC source: 0000874015-26-000138 · edgardoc.xml · nonDerivative · entry 3 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 23:13 UTC |
Baroldi JosephEVP, Chief Business Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 238 | $0.00 Strike: $56.78 | $0.00 |
DisclosureSEC source: 0000874015-26-000133 · edgardoc.xml · derivative · entry 13 Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer 10b5-1 filing: Plan reported Ownership: Indirect · by Spouse Disclosed balance after: 3,866 Underlying: Common Stock · 238 shares Expires 2028-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 23:13 UTC |
Baroldi JosephEVP, Chief Business Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 201 | $0.00 Strike: $32.60 | $0.00 |
DisclosureSEC source: 0000874015-26-000133 · edgardoc.xml · derivative · entry 11 Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer 10b5-1 filing: Plan reported Ownership: Indirect · by Spouse Disclosed balance after: 1,769 Underlying: Common Stock · 201 shares Expires 2032-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 23:13 UTC |
Baroldi JosephEVP, Chief Business Officer
|
SaleCommon Stock | 201 | $80.00 | $16,080.00 |
DisclosureSEC source: 0000874015-26-000133 · edgardoc.xml · nonDerivative · entry 9 Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer 10b5-1 filing: Plan reported Ownership: Indirect · by Spouse Disclosed balance after: 4,347 F2 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting persons spouse on November 25, 2025. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 23:13 UTC |
Baroldi JosephEVP, Chief Business Officer
|
Exercise / conversionCommon Stock | 201 | $32.60 | $6,552.60 |
DisclosureSEC source: 0000874015-26-000133 · edgardoc.xml · nonDerivative · entry 8 Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer 10b5-1 filing: Plan reported Ownership: Indirect · by Spouse Disclosed balance after: 4,548 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 23:13 UTC |
Baroldi JosephEVP, Chief Business Officer
|
SaleCommon Stock | 238 | $80.00 | $19,040.00 |
DisclosureSEC source: 0000874015-26-000133 · edgardoc.xml · nonDerivative · entry 7 Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer 10b5-1 filing: Plan reported Ownership: Indirect · by Spouse Disclosed balance after: 4,347 F2 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting persons spouse on November 25, 2025. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 23:13 UTC |
Baroldi JosephEVP, Chief Business Officer
|
Exercise / conversionCommon Stock | 238 | $56.78 | $13,513.64 |
DisclosureSEC source: 0000874015-26-000133 · edgardoc.xml · nonDerivative · entry 6 Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer 10b5-1 filing: Plan reported Ownership: Indirect · by Spouse Disclosed balance after: 4,585 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC |
LOSCALZO JOSEPHDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 832 | $0.00 Strike: $38.06 | $0.00 |
DisclosureSEC source: 0000874015-26-000138 · edgardoc.xml · derivative · entry 5 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,168 Underlying: Common Stock · 832 shares Expires 2032-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC |
LOSCALZO JOSEPHDirector
|
SaleCommon Stock | 832 | $80.33 | $66,832.81 |
DisclosureSEC source: 0000874015-26-000138 · edgardoc.xml · nonDerivative · entry 2 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,330 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 18, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.035 to $81.01 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC |
LOSCALZO JOSEPHDirector
|
Exercise / conversionCommon Stock | 832 | $38.06 | $31,665.92 |
DisclosureSEC source: 0000874015-26-000138 · edgardoc.xml · nonDerivative · entry 1 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC |
Devers Shannon L.EVP, Chief Human Resources Ofc
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 385 | $0.00 Strike: $52.87 | $0.00 |
DisclosureSEC source: 0000874015-26-000135 · edgardoc.xml · derivative · entry 13 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,877 Underlying: Common Stock · 385 shares Expires 2034-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC |
Devers Shannon L.EVP, Chief Human Resources Ofc
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,760 | $0.00 Strike: $40.85 | $0.00 |
DisclosureSEC source: 0000874015-26-000135 · edgardoc.xml · derivative · entry 12 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,280 Underlying: Common Stock · 3,760 shares Expires 2034-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC |
Devers Shannon L.EVP, Chief Human Resources Ofc
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,510 | $0.00 Strike: $37.58 | $0.00 |
DisclosureSEC source: 0000874015-26-000135 · edgardoc.xml · derivative · entry 11 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,744 Underlying: Common Stock · 3,510 shares Expires 2033-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC |
Devers Shannon L.EVP, Chief Human Resources Ofc
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,500 | $0.00 Strike: $34.69 | $0.00 |
DisclosureSEC source: 0000874015-26-000135 · edgardoc.xml · derivative · entry 10 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 5,500 shares Expires 2035-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC |
Devers Shannon L.EVP, Chief Human Resources Ofc
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 6,951 | $0.00 Strike: $32.60 | $0.00 |
DisclosureSEC source: 0000874015-26-000135 · edgardoc.xml · derivative · entry 9 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 928 Underlying: Common Stock · 6,951 shares Expires 2032-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC |
Devers Shannon L.EVP, Chief Human Resources Ofc
|
SaleCommon Stock | 755 | $80.84 | $61,031.94 |
DisclosureSEC source: 0000874015-26-000135 · edgardoc.xml · nonDerivative · entry 8 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,541 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 24, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.76 to $81.01 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC |
Devers Shannon L.EVP, Chief Human Resources Ofc
|
SaleCommon Stock | 5,030 | $80.00 | $402,394.97 |
DisclosureSEC source: 0000874015-26-000135 · edgardoc.xml · nonDerivative · entry 7 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,296 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 24, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.68 to $80.675 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC |
Devers Shannon L.EVP, Chief Human Resources Ofc
|
SaleCommon Stock | 14,321 | $79.12 | $1,133,005.92 |
DisclosureSEC source: 0000874015-26-000135 · edgardoc.xml · nonDerivative · entry 6 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,326 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 24, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.61 to $79.60 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC |
Devers Shannon L.EVP, Chief Human Resources Ofc
|
Exercise / conversionCommon Stock | 385 | $52.87 | $20,354.95 |
DisclosureSEC source: 0000874015-26-000135 · edgardoc.xml · nonDerivative · entry 5 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,647 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC |
Devers Shannon L.EVP, Chief Human Resources Ofc
|
Exercise / conversionCommon Stock | 6,951 | $32.60 | $226,602.60 |
DisclosureSEC source: 0000874015-26-000135 · edgardoc.xml · nonDerivative · entry 4 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,262 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC |
Devers Shannon L.EVP, Chief Human Resources Ofc
|
Exercise / conversionCommon Stock | 5,500 | $34.69 | $190,795.00 |
DisclosureSEC source: 0000874015-26-000135 · edgardoc.xml · nonDerivative · entry 3 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,311 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC |
Devers Shannon L.EVP, Chief Human Resources Ofc
|
Exercise / conversionCommon Stock | 3,760 | $40.85 | $153,596.00 |
DisclosureSEC source: 0000874015-26-000135 · edgardoc.xml · nonDerivative · entry 2 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,811 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC |
Devers Shannon L.EVP, Chief Human Resources Ofc
|
Exercise / conversionCommon Stock | 3,510 | $37.58 | $131,905.80 |
DisclosureSEC source: 0000874015-26-000135 · edgardoc.xml · nonDerivative · entry 1 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,051 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $42.88 | $0.00 |
DisclosureSEC source: 0000874015-26-000137 · edgardoc.xml · derivative · entry 8 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2028-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $40.05 | $0.00 |
DisclosureSEC source: 0000874015-26-000137 · edgardoc.xml · derivative · entry 7 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2031-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC |
KLEIN JOSEPH IIIDirector
|
SaleCommon Stock | 1,012 | $80.82 | $81,787.82 |
DisclosureSEC source: 0000874015-26-000137 · edgardoc.xml · nonDerivative · entry 5 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,014 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.67 to $81.025 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC |
KLEIN JOSEPH IIIDirector
|
SaleCommon Stock | 6,794 | $80.00 | $543,486.03 |
DisclosureSEC source: 0000874015-26-000137 · edgardoc.xml · nonDerivative · entry 4 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,026 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.65 to $80.63 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC |
KLEIN JOSEPH IIIDirector
|
SaleCommon Stock | 13,526 | $79.17 | $1,070,907.52 |
DisclosureSEC source: 0000874015-26-000137 · edgardoc.xml · nonDerivative · entry 3 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,820 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.615 to $79.60 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionCommon Stock | 4,000 | $42.88 | $171,520.00 |
DisclosureSEC source: 0000874015-26-000137 · edgardoc.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,346 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionCommon Stock | 12,000 | $40.05 | $480,600.00 |
DisclosureSEC source: 0000874015-26-000137 · edgardoc.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,346 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC |
Diaz Allene M.Director
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,321 | $0.00 Strike: $41.08 | $0.00 |
DisclosureSEC source: 0000874015-26-000136 · edgardoc.xml · derivative · entry 9 Diaz Allene M. · CIK 0001773314 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,321 shares Expires 2033-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC |
Diaz Allene M.Director
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $40.05 | $0.00 |
DisclosureSEC source: 0000874015-26-000136 · edgardoc.xml · derivative · entry 8 Diaz Allene M. · CIK 0001773314 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires 2031-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC |
Diaz Allene M.Director
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $38.06 | $0.00 |
DisclosureSEC source: 0000874015-26-000136 · edgardoc.xml · derivative · entry 7 Diaz Allene M. · CIK 0001773314 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2032-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC |
Diaz Allene M.Director
|
SaleCommon Stock | 1,005 | $80.80 | $81,203.00 |
DisclosureSEC source: 0000874015-26-000136 · edgardoc.xml · nonDerivative · entry 6 Diaz Allene M. · CIK 0001773314 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,811 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.61 to $81.01 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC |
Diaz Allene M.Director
|
SaleCommon Stock | 14,608 | $79.88 | $1,166,814.00 |
DisclosureSEC source: 0000874015-26-000136 · edgardoc.xml · nonDerivative · entry 5 Diaz Allene M. · CIK 0001773314 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,816 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.57to $80.55 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC |
Diaz Allene M.Director
|
SaleCommon Stock | 39,265 | $79.11 | $3,106,411.21 |
DisclosureSEC source: 0000874015-26-000136 · edgardoc.xml · nonDerivative · entry 4 Diaz Allene M. · CIK 0001773314 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,424 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.565 to $79.565 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC |
Diaz Allene M.Director
|
Exercise / conversionCommon Stock | 18,000 | $40.05 | $720,900.00 |
DisclosureSEC source: 0000874015-26-000136 · edgardoc.xml · nonDerivative · entry 3 Diaz Allene M. · CIK 0001773314 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC |
Diaz Allene M.Director
|
Exercise / conversionCommon Stock | 12,000 | $38.06 | $456,720.00 |
DisclosureSEC source: 0000874015-26-000136 · edgardoc.xml · nonDerivative · entry 2 Diaz Allene M. · CIK 0001773314 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC |
Diaz Allene M.Director
|
Exercise / conversionCommon Stock | 10,321 | $41.08 | $423,986.68 |
DisclosureSEC source: 0000874015-26-000136 · edgardoc.xml · nonDerivative · entry 1 Diaz Allene M. · CIK 0001773314 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:13 UTC |
BENNETT C FRANKEVP, Chief Scientific Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 48,626 | $0.00 Strike: $60.89 | $0.00 |
DisclosureSEC source: 0000874015-26-000134 · edgardoc.xml · derivative · entry 7 BENNETT C FRANK · CIK 0001073387 · EVP, Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 48,626 shares Expires 2027-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:13 UTC |
BENNETT C FRANKEVP, Chief Scientific Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 16,463 | $0.00 Strike: $32.60 | $0.00 |
DisclosureSEC source: 0000874015-26-000134 · edgardoc.xml · derivative · entry 6 BENNETT C FRANK · CIK 0001073387 · EVP, Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,406 Underlying: Common Stock · 16,463 shares Expires 2032-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:13 UTC |
BENNETT C FRANKEVP, Chief Scientific Officer
|
SaleCommon Stock | 802 | $80.76 | $64,771.12 |
DisclosureSEC source: 0000874015-26-000134 · edgardoc.xml · nonDerivative · entry 5 BENNETT C FRANK · CIK 0001073387 · EVP, Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,554 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 19, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.61 to $81.07 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:13 UTC |
BENNETT C FRANKEVP, Chief Scientific Officer
|
SaleCommon Stock | 12,687 | $79.88 | $1,013,409.65 |
DisclosureSEC source: 0000874015-26-000134 · edgardoc.xml · nonDerivative · entry 4 BENNETT C FRANK · CIK 0001073387 · EVP, Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,356 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 19, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.605 to $80.555 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:13 UTC |
BENNETT C FRANKEVP, Chief Scientific Officer
|
SaleCommon Stock | 71,600 | $79.10 | $5,663,488.40 |
DisclosureSEC source: 0000874015-26-000134 · edgardoc.xml · nonDerivative · entry 3 BENNETT C FRANK · CIK 0001073387 · EVP, Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,043 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 19, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.60 to $79.60 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:13 UTC |
BENNETT C FRANKEVP, Chief Scientific Officer
|
Exercise / conversionCommon Stock | 48,626 | $60.89 | $2,960,837.14 |
DisclosureSEC source: 0000874015-26-000134 · edgardoc.xml · nonDerivative · entry 2 BENNETT C FRANK · CIK 0001073387 · EVP, Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 165,643 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:13 UTC |
BENNETT C FRANKEVP, Chief Scientific Officer
|
Exercise / conversionCommon Stock | 16,463 | $32.60 | $536,693.80 |
DisclosureSEC source: 0000874015-26-000134 · edgardoc.xml · nonDerivative · entry 1 BENNETT C FRANK · CIK 0001073387 · EVP, Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,017 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:13 UTC |
Baroldi JosephEVP, Chief Business Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 820 | $0.00 Strike: $56.78 | $0.00 |
DisclosureSEC source: 0000874015-26-000133 · edgardoc.xml · derivative · entry 12 Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer 10b5-1 filing: Plan reported Ownership: Indirect · by Spouse Disclosed balance after: 4,104 Underlying: Common Stock · 820 shares Expires 2028-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:13 UTC |
Baroldi JosephEVP, Chief Business Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 879 | $0.00 Strike: $32.60 | $0.00 |
DisclosureSEC source: 0000874015-26-000133 · edgardoc.xml · derivative · entry 10 Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer 10b5-1 filing: Plan reported Ownership: Indirect · by Spouse Disclosed balance after: 1,970 Underlying: Common Stock · 879 shares Expires 2032-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:13 UTC |
Baroldi JosephEVP, Chief Business Officer
|
SaleCommon Stock | 36 | $81.01 | $2,916.36 |
DisclosureSEC source: 0000874015-26-000133 · edgardoc.xml · nonDerivative · entry 5 Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer 10b5-1 filing: Plan reported Ownership: Indirect · by Spouse Disclosed balance after: 4,347 F2 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting persons spouse on November 25, 2025. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:13 UTC |
Baroldi JosephEVP, Chief Business Officer
|
SaleCommon Stock | 2,088 | $80.41 | $167,891.70 |
DisclosureSEC source: 0000874015-26-000133 · edgardoc.xml · nonDerivative · entry 4 Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer 10b5-1 filing: Plan reported Ownership: Indirect · by Spouse Disclosed balance after: 4,383 F2 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting persons spouse on November 25, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.94 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.